This is an update to the article titled, "Third Update to 'HHSC to Reopen Respiratory Syncytial Virus Season for Select Texas Regions.'"
Beginning June 21, 2021, The Texas Health and Human Services Commission (HHSC) began opening the Department of State Health Services (DSHS) regions for Respiratory Syncytial Virus (RSV) prophylaxis with Palivizumab (Synagis) for clients currently meeting clinical criteria. This is in response to the infections in Texas which typically occur during the fall and winter months.
HHSC observed very little activity during the traditional 2020-21 season, which was likely due to the adoption of public health measures to reduce the spread of COVID-19 (e.g., physical distancing, masking, etc.). This period of unusually low activity has been followed during the late spring and summer months by an unusual resurgence of RSV activity. Refer to the RSV season schedule for more information.
On July 23, 2021, HHSC will open all DSHS regions, and providers can start monthly Palivizumab (Synagis) injections for RSV prophylaxis for clients who meet clinical criteria. This reopening is considered the start of a new RSV season and is separate from the regular 2020-2021 RSV season. At this time, clients who meet the prior authorization criteria qualify for up to 5 monthly shots of Palivizumab (Synagis).
HHSC cannot account for every exception or all potential clinical considerations applicable to an individual client’s case. Providers must work with the individual managed care organization (MCO) for approval for clients with RSV infection risks not identified on the Medicaid RSV prior authorization form. The reconsideration process may require additional supporting documents, such as pertinent diagnostic, lab tests, or medical records.
The recent summer resurgence in RSV activity is unprecedented and continues to evolve. At this time, it is not possible to anticipate how this inter-seasonal activity will impact the traditional 2021-22 RSV season. HHSC remains in active communication with DSHS, the Texas Pediatric Society, and the RSV Task Force. Further guidance will be announced as new developments arise.
Email email@example.com with questions or comments.